Dry Eye Syndrome

Dry eye syndrome is a multifactorial ocular-surface disorder involving inadequate tear production, excessive evaporation, or instability of the tear film. Its clinical burden is shaped by aging, prolonged digital-device use, contact-lens wear, environmental exposure, systemic disease, medication use, and ocular procedures. Effective management increasingly requires individualized diagnosis, longitudinal monitoring, and treatment of both symptoms and underlying tear-film dysfunction.

The dry-eye landscape is shifting from episodic symptom relief toward structured ocular-surface care. Clinicians are placing greater emphasis on distinguishing aqueous-deficient, evaporative, and mixed disease; evaluating eyelid and meibomian-gland function; and identifying inflammatory, medication-related, or behavioral contributors. Care pathways are also becoming more integrated, combining environmental modification, lubricants, lid hygiene, prescription therapies, procedural options, and follow-up based on treatment response.

Artificial intelligence can strengthen dry-eye care by supporting image interpretation, tear-film and blink analysis, symptom-pattern classification, and identification of patients who may require specialist assessment. Its cumulative value depends on high-quality, representative clinical data and validation across devices, skin tones, age groups, and care settings. AI should support-not replace-clinical judgment, particularly because symptoms and objective signs may diverge and treatment decisions require examination of the whole ocular surface.

In North America, awareness, specialist access, and adoption of diagnostic technologies support structured management, while screen exposure and an aging population sustain demand for care. Europe combines established ophthalmic services with regulatory and reimbursement variation across countries. Asia-Pacific faces a large and diverse patient base, urban pollution, digital-device exposure, and uneven access between metropolitan and rural settings. Latin America is influenced by healthcare-access disparities, climatic conditions, and growing attention to ophthalmic screening. In the Middle East, arid environments, heat, dust, and intensive indoor air-conditioning can aggravate symptoms, while access varies by health system. Africa presents substantial unmet need linked to specialist shortages, affordability constraints, limited diagnostic infrastructure, and environmental exposure.

ASEAN members face diverse climates, rapid urbanization, expanding digital exposure, and uneven ophthalmic capacity, making scalable primary-care screening important. BRICS countries combine major urban specialist centers with substantial geographic and affordability gaps, creating a need for practical diagnostic protocols and broader access to essential treatment. The European Union benefits from coordinated scientific and regulatory frameworks, although national reimbursement and service pathways remain distinct. G7 health systems generally have stronger specialist infrastructure but must address aging populations, chronic disease, and care costs. GCC countries must account for arid conditions, dust, and indoor climate exposure alongside concentrated specialist capacity. NATO members span varied health systems, yet military and civilian populations alike may benefit from standardized ocular-surface screening and evidence-based referral pathways.

Australia’s sun, wind, low-humidity conditions, and dispersed population make prevention and remote access relevant. Brazil and Mexico must address climatic diversity, urban pollution, and unequal specialist access. Canada and the United States face aging, digital-device exposure, medication-related risk, and differences in coverage and care affordability. China and India combine extensive patient populations with rapid urbanization and highly variable access between major cities and rural areas. Japan and South Korea have advanced ophthalmic capabilities while confronting aging and intensive digital-device use. France, Germany, Italy, Spain, and the United Kingdom have established clinical services, but national pathways, reimbursement, and waiting times differ. Russia’s large geography and regional variation make continuity of diagnosis and treatment an important consideration.

Industry leaders should prioritize validated, patient-centered solutions that address distinct dry-eye mechanisms rather than relying on symptom relief alone. Key actions include developing interoperable diagnostic tools, generating real-world evidence across diverse populations, simplifying adherence through convenient regimens, and supporting clinician education on differential diagnosis and stepwise care. Partnerships with primary-care providers, pharmacists, employers, and digital-health services can improve earlier recognition, while transparent AI governance, post-market monitoring, and attention to affordability can strengthen trust and access.

This executive summary uses a structured synthesis of established clinical concepts and publicly recognized epidemiological, healthcare-delivery, technology, and environmental drivers relevant to dry eye syndrome. The assessment organizes findings by disease mechanisms, care pathways, artificial-intelligence applications, geography, and cross-national groupings. Regional and country narratives are qualitative and comparative; they do not imply market estimates, market sizing, market shares, or forecasts. Interpretation should be updated as clinical guidance, regulatory requirements, diagnostic validation, and reimbursement conditions evolve.

Dry eye syndrome is increasingly understood as a chronic, heterogeneous ocular-surface condition requiring more precise assessment and sustained management. Progress will depend on combining mechanism-based treatment, practical prevention, equitable access, and validated digital tools. Health systems and industry leaders that connect objective testing with patient-reported outcomes, strengthen clinician capability, and adapt care to local environmental and demographic realities will be better positioned to improve long-term ocular comfort and function.